In this exclusive report, Cure, a healthcare innovation ecosystem in New York City, and the Deerfield Institute unveil the results of a specialty physician survey, shedding light on their current prescribing of GLP-1RA medications, the challenges they face, and their expectations for future clinical applications of these drugs
But my clinical position remains clear: I do not recommend BPC 157 as a treatment for Crohn's disease or ulcerative colitis, and I remain highly skeptical
These effects result in edema, demyelination, and peripheral nerve necrosis, impairing nerve conduction
Pricing, side effects, and objectives all matter
None of these things are inherently bad